These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 1311741)

  • 41. Time course of distribution to tissues of 125I-somatomedin A injected into the rat.
    Kawai K; Takano K; Hizuka N; Shizume K
    Endocrinol Jpn; 1979 Dec; 26(6):667-73. PubMed ID: 540567
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterisation of CHAPS-solubilised active erythropoietin receptors from Rauscher erythroleukaemic cells using biotinylated erythropoietin.
    Afrasiabi M; Elder GE; Lappin TR; Bridges JM
    Biochem Soc Trans; 1991 Feb; 19(1):34S. PubMed ID: 1645313
    [No Abstract]   [Full Text] [Related]  

  • 43. A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans.
    Veng-Pedersen P; Widness JA; Pereira LM; Schmidt RL; Lowe LS
    Biopharm Drug Dispos; 1999 May; 20(4):217-23. PubMed ID: 10440797
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radioimmunoassay of erythropoietin.
    Garcia JF; Sherwood J; Goldwasser E
    Blood Cells; 1979 Aug; 5(3):405-19. PubMed ID: 555695
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel radioimmunoassay for human erythropoietin using a synthetic NH2-terminal polypeptide and anti-peptide antibodies.
    Sytkowski AJ; Sue JM
    J Immunol Methods; 1984 Apr; 69(2):181-6. PubMed ID: 6715890
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overestimate of 125I-protein uptake from the adult mouse gut.
    Skogh T
    Gut; 1982 Dec; 23(12):1077-80. PubMed ID: 7173719
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of 125I-interferons in pharmacokinetic and tissue distribution studies.
    Palleroni AV; Bohoslawec O
    J Interferon Res; 1984; 4(4):493-8. PubMed ID: 6501942
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of PM-2 DNA degradation as a pharmacokinetic assay for bleomycin.
    Galvan L; Strong JE; Crooke ST
    Cancer Res; 1979 Oct; 39(10):3948-51. PubMed ID: 89893
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A two-cycle immunoprecipitation procedure for reducing nonspecific protein contamination.
    Doolittle MH; Martin DC; Davis RC; Reuben MA; Elovson J
    Anal Biochem; 1991 Jun; 195(2):364-8. PubMed ID: 1750692
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Studies on a radioimmunoassay for human erythopoietin.
    Lertora JJ; Dargon PA; Rege AB; Fisher JW
    J Lab Clin Med; 1975 Jul; 86(1):140-51. PubMed ID: 1151136
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trichloroacetic acid (TCA) precipitability of 125I in the blood of mice fed 125I.
    Harmatz PR; Walsh MK; Walker WA; Hanson DG; Bloch KJ
    J Immunol Methods; 1987 Sep; 102(2):213-9. PubMed ID: 3655373
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A tracer interaction method for nonlinear pharmacokinetics analysis: application to evaluation of nonlinear elimination.
    Veng-Pedersen P; Widness JA; Wang J; Schmidt RL
    J Pharmacokinet Biopharm; 1997 Oct; 25(5):569-93. PubMed ID: 9679223
    [TBL] [Abstract][Full Text] [Related]  

  • 53. From old results to new perspectives: a look at interferon's fate in the body.
    Diez RA; Perdereau B; Falcoff E
    J Interferon Res; 1987 Oct; 7(5):553-7. PubMed ID: 2445853
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Erythropoietin].
    Kozuru M; Noda Y; Umemura H
    Nihon Rinsho; 1979 Jun; Suppl():2121-2. PubMed ID: 491091
    [No Abstract]   [Full Text] [Related]  

  • 55. Studies on the role of sialic acid in the physical and biological properties of erythropoietin.
    Lukowsky WA; Painter RH
    Can J Biochem; 1972 Aug; 50(8):909-17. PubMed ID: 5080374
    [No Abstract]   [Full Text] [Related]  

  • 56. Purification of erythropoietin.
    Goldwasser E; Kung CK
    Proc Natl Acad Sci U S A; 1971 Apr; 68(4):697-8. PubMed ID: 5279510
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Erythropoietin assay.
    Oliver LK; Gould R
    Br J Haematol; 1978 Feb; 38(2):295-6. PubMed ID: 638078
    [No Abstract]   [Full Text] [Related]  

  • 58. Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer.
    Yan S; Fang J; Chen Y; Xie Y; Zhang S; Zhu X; Fang F
    BMC Cancer; 2020 Dec; 20(1):1205. PubMed ID: 33287740
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overlooked Issues on Pharmacokinetics Data Interpretation of Protein Drugs-a Case Example of Erythropoietin.
    An G; Schmidt RL; Mock DM; Veng-Pedersen P; Widness JA
    AAPS J; 2018 Nov; 21(1):6. PubMed ID: 30478521
    [No Abstract]   [Full Text] [Related]  

  • 60. Differential pharmacokinetic analysis of in vivo erythropoietin receptor interaction with erythropoietin and continuous erythropoietin receptor activator in sheep.
    El-Komy MH; Schmidt RL; Widness JA; Veng-Pedersen P
    Biopharm Drug Dispos; 2011 Jul; 32(5):276-88. PubMed ID: 21678432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.